MGRX Stock Catalyst: Mangoceuticals Launches Direct Access Programs for Zepbound and Wegovy

Nov 12, 2025 · 7:07pm ET

Company introduces MangoRx Direct and PeachesRx Direct for weight management medications.

Max move

+56.5%

High of day $2.88

Sparker timei

7:07pm ET

MGRX · Nov 12, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Mangoceuticals, Inc. announced on November 13, 2025, the launch of two new programs: MangoRx Direct and PeachesRx Direct. These initiatives aim to offer direct access to Zepbound and Wegovy, medications used for weight management.

The MangoRx Direct program is priced at $99 per month, while the PeachesRx Direct program is set at $499 per month. These programs are part of Mangoceuticals' strategy to enhance patient access to critical medications.

As of the latest company context, Mangoceuticals has a free float of 10,163,800 shares and 11,435,800 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time MGRX sparks.

Download Sniper App →

Catch the next MGRX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →